Diagnostic sensitivity and specificity of CD34, parathyroid hormone-related protein (with antisera C6 and C7), parathyroid hormone1 receptor, osteoprotegerin and receptor activator of nuclear factor-κ B ligand to distinguish patients with low-grade and high-grade prostate carcinoma
| Cut-off* | Low-grade PCa (⩾ cut-off/total) | High-grade PCa (⩾ cut-off/total) | Sensitivity (95% CI) (%) | Specificity (95% CI) (%) | |
|---|---|---|---|---|---|
| PCa, prostate carcinoma; PTH1R, parathyroid hormone1 receptor; PTHrP, parathyroid hormone-related protein; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κ B ligand. | |||||
| *The score values used as reference limits were: 1, 2 and 3 (for CD34); quartile 1, moderate staining (4), and quartile 3 (for each bone cytokine studied), as described in the text. | |||||
| CD34 | 1 | (22/22) | (23/23) | 100 | 0 |
| 2 | (9/22) | (19/23) | 83 (72 to 94) | 59 (45 to 73) | |
| 3 | (2/22) | (5/23) | 22 (10 to 34) | 91 (83 to 99) | |
| PTHrP-C6 | 3 | (15/22) | (25/25) | 100 | 32 (19 to 45) |
| 4 | (10/22) | (25/25) | 100 | 54 (40 to 68) | |
| 6 | (7/22) | (23/25) | 92 (84 to 100) | 68 (55 to 81) | |
| PTHrP-C7 | 2 | (14/22) | (23/25) | 96 (90 to 100) | 36 (22 to 50) |
| 4 | (8/22) | (21/25) | 84 (74 to 94) | 64 (50 to 78) | |
| 6 | (6/22) | (12/25) | 48 (34 to 62) | 73 (60 to 86) | |
| PTH1R | 3 | (15/22) | (24/25) | 96 (90 to 100) | 32 (19 to 45) |
| 4 | (11/22) | (22/25) | 88 (79 to 97) | 50 (36 to 64) | |
| 6 | (9/22) | (18/25) | 72 (59 to 85) | 59 (45 to 73) | |
| OPG | 2 | (21/22) | (25/25) | 100 | 4 (0 to 10) |
| 4 | (12/22) | (21/25) | 84 (74 to 94) | 45 (31 to 59) | |
| 6 | (1/22) | (14/25) | 56 (42 to 70) | 95 (89 to 100) | |
| RANKL | 2 | (14/22) | (23/25) | 92 (84 to 100) | 36 (22 to 50) |
| 4 | (1/22) | (18/25) | 72 (59 to 85) | 95 (89 to 100) | |
| 6 | (0/22) | (13/25) | 52 (38 to 66) | 100 | |